Eli Lilly and NRAS Launch Film for RA Awareness Week
Eli Lilly and Company and the National Rheumatoid Arthritis Society (NRAS) announced the launch of a new film, called Behind the Smile. The film encourages people living with rheumatoid arthritis (RA) to have an open conversation with their doctor or nurse about how they are really feeling, and how their disease impacts their day-to-day life.
Eli Lilly and Company and the National Rheumatoid Arthritis Society (NRAS) announced the launch of a new film-Behind the Smile. The film encourages people with rheumatoid arthritis (RA) to speak openly with their doctor or nurse about how they really feel and how their disease effects their daily life.
In conjunction with RA Awareness Week (June 19-25), the film’s goal is to increase awareness of physical and emotional struggles that people with RA deal with every day, and encourage healthcare professionals to listen to what really matters to the individual patient.
Behind the Smile is launched to coincide with the results from the new survey by Lilly, RA Matters, which reveals a lack of understanding about the true impact of RA. To view the film, visit http://www.nras.org.uk/behindthesmile.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Talphera Cuts NEPHRO CRRT Study Size, Secures $14.8 Million Private Placement
April 1st 2025The trial size adjustment, along with protocol modifications and the addition of higher-enrollment sites, is expected to facilitate completion of the NEPHRO CRRT study of Niyad in patients undergoing renal replacement therapy by the end of 2025.
